Protillion Biosciences is a biotechnology startup that operates in the field of therapeutic protein discovery and optimization. The company uses next-generation technologies to generate quantitative protein data at an unprecedented scale, aiming to bring the best therapeutic candidates to light. Their primary clients are likely to be pharmaceutical companies and research institutions that are involved in drug discovery and development.

Protillion's business model revolves around the use of revolutionary technology to quantitatively characterize protein candidates at a massive scale. This allows them to discover therapeutic molecules with precisely tuned affinity and uncompromised manufacturability. The company's high throughput protein analysis chip and comprehensive quantitative data for the entire library are key components of this process.

The company also emphasizes the importance of pairing revolutionary computational approaches to drug discovery with exceptional wet experimentation for training and validation. This suggests a hybrid approach that combines advanced technology with traditional laboratory methods.

Protillion recently raised $18 million in financing, led by ARCH Venture Partners and Illumina Ventures. This indicates strong financial backing and potential for growth.

In terms of revenue generation, while specific details are not provided, it's likely that Protillion makes money by licensing its technology and data to pharmaceutical companies and research institutions, and potentially through partnerships and collaborations in drug discovery and development.

Keywords: Biotechnology, Therapeutic Protein Discovery, Next-Generation Technologies, Drug Discovery, Pharmaceutical Companies, Research Institutions, High Throughput Protein Analysis, Quantitative Protein Data, Computational Approaches, Wet Experimentation.